Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals

被引：42

作者：

Grant, Philip M. ^{[1
]}

Kitch, Douglas ^{[3
]}

McComsey, Grace A. ^{[5
,6
]}

Collier, Ann C. ^{[8
]}

Koletar, Susan L. ^{[7
]}

Erlandson, Kristine M. ^{[9
]}

Yin, Michael T. ^{[10
]}

Bartali, Benedetta ^{[4
]}

Ha, Belinda ^{[11
]}

Melbourne, Kathy ^{[2
]}

Brown, Todd T. ^{[12
]}

机构：

[1] Stanford Univ, Dept Med, Div Infect Dis, Palo Alto, CA 94304 USA

[2] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[3] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA USA

[4] New England Res Inst, 9 Galen St, Watertown, MA 02172 USA

[5] Case Western Reserve Univ, Dept Pediat, Div Infect Dis, Cleveland, OH 44106 USA

[6] Case Western Reserve Univ, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA

[7] Ohio State Univ, Dept Med, Div Infect Dis, Columbus, OH 43210 USA

[8] Univ Washington, Dept Med, Div Infect Dis, Seattle, WA USA

[9] Univ Colorado, Div Infect Dis, Dept Med, Aurora, CO USA

[10] Columbia Univ, Dept Med, Div Infect Dis, New York, NY USA

[11] Viiv Healthcare, Res Triangle Pk, NC USA

[12] Johns Hopkins Univ, Dept Med, Div Endocrinol Diabet & Metab, Baltimore, MD USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2016年 / 214卷 / 04期

关键词：

anti-HIV agents; administration and dosage; adverse effects; HIV infections; drug therapy/virology; bone density; TENOFOVIR DISOPROXIL FUMARATE; HIV-1-INFECTED PATIENTS; THERAPY INITIATION; EMTRICITABINE; COMBINATION; LAMIVUDINE; EFAVIRENZ; ABACAVIR; TRIALS; WOMEN;

D O I：

10.1093/infdis/jiw204

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5 years after antiretroviral therapy (ART) initiation and HIV-uninfected controls. HIV-infected individuals (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96 weeks of ART. Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate of decline in HIV-uninfected individuals at the lumbar spine but not at the hip. In HIV-infected individuals after 96 weeks, no HIV- or treatment-related characteristic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at both lumbar spine and hip.

引用

页码：607 / 611

页数：5

共 15 条

[1]

Racial/Ethnic and Socioeconomic Differences in Bone Loss Among Men [J].

Araujo, Andre B. ;

Yang, May ;

Suarez, Elizabeth A. ;

Dagincourt, Nicholas ;

Abraham, Jonathan R. ;

Chiu, Gretchen ;

Holick, Michael F. ;

Bouxsein, Mary L. ;

Zmuda, Joseph M. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (12) :2552-2560

[2]

Stable Bone Density in HAART-Treated Individuals with HIV: A Meta-Analysis [J].

Bolland, Mark J. ;

Wang, Tom K. M. ;

Grey, Andrew ;

Gamble, Greg D. ;

Reid, Ian R. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (09) :2721-2731

[3]

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review [J].

Brown, Todd T. ;

Qaqish, Roula B. .

AIDS, 2006, 20 (17) :2165-2174

[4]

Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen [J].

Brown, Todd T. ;

McComsey, Grace A. ;

King, Martin S. ;

Qaqish, Roula B. ;

Bernstein, Barry M. ;

da Silva, Barbara A. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (05) :554-561

[5]

Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation [J].

Grant, Philip M. ;

Kitch, Douglas ;

McComsey, Grace A. ;

Dube, Michael P. ;

Haubrich, Richard ;

Huang, Jeannie ;

Riddler, Sharon ;

Tebas, Pablo ;

Zolopa, Andrew R. ;

Collier, Ann C. ;

Brown, Todd T. .

CLINICAL INFECTIOUS DISEASES, 2013, 57 (10) :1483-1488

[6]

Gupta SK, 2015, IAS C HIV PATH TREAT

[7]

Change in lean body mass is a major determinant of change in areal bone mineral density of the proximal femur: A 12-year observational study [J].

Liu-Ambrose, T. ;

Kravetsky, L. ;

Bailey, D. ;

Sherar, L. ;

Mundt, C. ;

Baxter-Jones, A. ;

Khan, K. M. ;

McKay, H. A. .

CALCIFIED TISSUE INTERNATIONAL, 2006, 79 (03) :145-151

[8]

The safety and efficacy of switching stavuldine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: Three-year follow-up after switching therapy [J].

Madruga, Jose Valdez R. ;

Cassetti, Isabel ;

Suleiman, Jamal Muhamad A. H. ;

Etzel, Arnaldo ;

Zhong, Lijie ;

Holmes, Charles B. ;

Cheng, Andrew K. ;

Enejosa, Jeffrey .

HIV CLINICAL TRIALS, 2007, 8 (06) :381-390

[9]

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 [J].

McComsey, Grace A. ;

Kitch, Douglas ;

Daar, Eric S. ;

Tierney, Camlin ;

Jahed, Nasreen C. ;

Tebas, Pablo ;

Myers, Laurie ;

Melbourne, Kathleen ;

Ha, Belinda ;

Sax, Paul E. .

JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (12) :1791-1801

[10]

Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study) [J].

Negredo, Eugenia ;

Domingo, Pere ;

Perez-Alvarez, Nuria ;

Gutierrez, Mar ;

Mateo, Gracia ;

Puig, Jordi ;

Escrig, Roser ;

Echeverria, Patricia ;

Bonjoch, Anna ;

Clotet, Bonaventura .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (12) :3368-3371

← 1 2 →